Skip to main content
OpenTrials
Completed

NCT Number: NCT04381793

Treatment of CFS & Fibromyalgia With Recovery Factors

The study will explore if Recovery Factors improve symptoms in fibromyalgia and chronic fatigue syndrome

Completed

Looking for future studies?

Notify Me

Key information

About this study

Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet ACR 2010 amended Fibromyalgia criteria or CDC CFS Criteria Overall well being score of 5 of less (on 0-10 VAS)

Exclusion criteria

Pregnant Clotting disorders

-

Treatment and study plan

Recovery Factors

Dietary Supplement

Porcine serum amino acid/peptide

Primary outcomes

  1. VAS

    Time frame: 6 weeks

    Composite VAS (1-10) for Fatigue, Pain, Cognition, Sleep and overall well-being

Secondary outcomes

  1. antibody titres

    Time frame: 10 weeks

    Total IgG and IgG 1-4 subsets

  2. FIQ-R

    Time frame: 6 weeks

    Fibromyalgia severity scale

Sponsors and collaborators

Lead sponsor

Practitioners Alliance Network

Other

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
May 11, 2020
Registry last updated
Oct 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.